Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului
Yüklə 4,39 Mb.
|
| Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A10BD02 COMBINATII COMPR. FILM. 2,5 mg/400 mg (GLIBENCLAMIDUM + METFORMINUM) GLIBOMET(R) 2,5 mg/400 mg LAB. GUIDOTTI SPA
(GLIBENCLAMIDUM + METFORMINUM) GLIFORMIN 400 mg + 2.5 mg LABORMED PHARMA SA A10BD02 COMBINATII CAPS. 400 mg + 2.5 mg (GLIBENCLAMIDUM + METFORMINUM) BIDIAB 400 mg + 2.5 mg ARENA GROUP SA A10BD02 COMBINATII COMPR. FILM. 500 mg/2.5 mg (GLIBENCLAMIDUM + METFORMINUM) GLUCOVANCE(R) 500 mg/2.5 mg 500 mg/2.5 mg MERCK SANTE A10BD02 COMBINATII COMPR. FILM. 500 mg/5 mg (GLIBENCLAMIDUM + METFORMINUM) GLUCOVANCE(R) 500 mg/5 mg 500 mg/5 mg MERCK SANTE ________________________________________________________________________________
| 809 |A10BD03| COMBINATII (ROSIGLITAZONUM + | Protocol: A026E | | | | METFORMINUM)*** | | |_______|_______|____________________________________________|_________________| ________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A10BD03 COMBINATII COMPR. FILM. 1 mg/500 mg (ROSIGLITAZONUM + METFORMINUM) AVANDAMET 1 mg/500 mg 1 mg/500 mg SMITHKLINE BEECHAM PLC
(ROSIGLITAZONUM + METFORMINUM) AVANDAMET 2 mg/1000 mg 2 mg/1000 mg SMITHKLINE BEECHAM PLC A10BD03 COMBINATII COMPR. FILM. 2 mg/500 mg (ROSIGLITAZONUM + METFORMINUM) AVANDAMET 2 mg/500 mg 2 mg/500 mg SMITHKLINE BEECHAM PLC A10BD03 COMBINATII COMPR. FILM. 4 mg/1000 mg (ROSIGLITAZONUM + METFORMINUM) AVANDAMET 4 mg/1000 mg 4 mg/1000 mg SMITHKLINE BEECHAM PLC ________________________________________________________________________________
| 810 |A10BD04| COMBINATII (ROSIGLITAZONUM + | Protocol: A027E | | | | GLIMEPIRIDUM)*** | | |_______|_______|____________________________________________|_________________| ________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A10BD04 COMBINATII COMPR. FILM. 4 mg/4 mg (ROSIGLITAZONUM + GLIMEPIRIDUM) AVAGLIM 4 mg/4 mg 4 mg/4 mg SMITHKLINE BEECHAM PLC
(ROSIGLITAZONUM + GLIMEPIRIDUM) AVAGLIM 8 mg/4 mg 8 mg/4 mg SMITHKLINE BEECHAM PLC ________________________________________________________________________________
| 811 |A10BD05| COMBINATII (PIOGLITAZONUM + METFORMINUM)***| Protocol: A025E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A10BD05 COMBINATII COMPR. FILM. 15 mg/850 mg (PIOGLITAZONUM + METFORMINUM) COMPETACT 15 mg/850 mg TAKEDA GLOBAL RESEARCH AND DEVELOPMENT CENTRE LTD ________________________________________________________________________________
| 812 |A10BF01| ACARBOSUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A10BF01 ACARBOSUM COMPR. 100 mg GLUCOBAY(R) 100 100 mg BAYER HEALTHCARE AG
GLUCOBAY(R) 50 50 mg BAYER HEALTHCARE AG ________________________________________________________________________________
| 813 |A10BG02| ROSIGLITAZONUM*** | Protocol: A020E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A10BG02 ROSIGLITAZONUM COMPR. FILM. 4 mg AVANDIA 4 mg 4 mg SMITHKLINE BEECHAM PLC ________________________________________________________________________________ ______________________________________________________________________________ | 814 |A10BG03| PIOGLITAZONUM*** | Protocol: A020E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A10BG03 PIOGLITAZONUM COMPR. 15 mg ACTOS 15 mg 15 mg TAKEDA GLOBAL RESEARCH AND DEVELOPMENT CENTRE LTD A10BG03 PIOGLITAZONUM COMPR. 30 mg ACTOS 30 mg 30 mg TAKEDA GLOBAL RESEARCH AND DEVELOPMENT CENTRE LTD
ACTOS 45 mg 45 mg TAKEDA GLOBAL RESEARCH AND DEVELOPMENT CENTRE LTD ________________________________________________________________________________ ______________________________________________________________________________ | 815 |A10BH01| SITAGLIPTINUM*** | Protocol: A022E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A10BH01 SITAGLIPTINUM COMPR. FILM. 100 mg JANUVIA 100 mg 100 mg MERCK SHARP & DOHME LTD. ________________________________________________________________________________ ______________________________________________________________________________ | 816 |A10BX02| REPAGLINIDUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A10BX02 REPAGLINIDUM COMPR. 0.5 mg NOVONORM 0.5 mg 0.5 mg NOVO NORDISK A/S
NOVONORM 1 mg 1 mg NOVO NORDISK A/S A10BX02 REPAGLINIDUM COMPR. 2 mg NOVONORM 2 mg 2 mg NOVO NORDISK A/S ________________________________________________________________________________
| 817 |A10BX04| EXENATIDUM*** | Protocol: A028E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A10BX04 EXENATIDUM SOL. INJ. IN STILOU 10 µg/doza INJECTOR PREUMPLUT BYETTA 10 µg/doza 10 µg/doza ELI LILLY NEDERLAND BV A10BX04 EXENATIDUM SOL. INJ. IN STILOU 5 µg/doza INJECTOR PREUMPLUT BYETTA 5 µg/doza 5 µg/doza ELI LILLY NEDERLAND BV ________________________________________________________________________________ ______________________________________________________________________________ | 818 |A11DA03| BENFOTIAMINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A11DA03 BENFOTIAMINUM DRAJ. 50 mg BENFOGAMMA 50 mg WORWAG PHARMA GMBH & CO. KG ________________________________________________________________________________ ______________________________________________________________________________ | 819 |A11DBN1| COMBINATII** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A11DBN1 COMBINATII CAPS. MOI MILGAMMA(R) N WORWAG PHARMA GMBH & CO. KG A11DBN1 COMBINATII SOL. INJ. MILGAMMA(R) N WORWAG PHARMA GMBH & CO. KG ________________________________________________________________________________ ______________________________________________________________________________ | 820 |H04AA01| GLUCAGONUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H04AA01 GLUCAGONUM PULB. + SOLV. PT. SOL. 1 mg INJ. GLUCAGEN HYPOKIT 1 mg 1 mg NOVO NORDISK A/S ________________________________________________________________________________ SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.1: HEMOFILIE ŞI TALASEMIE ______________________________________________________________________________ | 827 |V03AC01| DEFEROXAMINUM**(3) | Protocol: V001D | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ V03AC01 DEFEROXAMINUM LIOF. PT. SOL. 500 mg INJ./PERF. DESFERAL 500 mg NOVARTIS PHARMA GMBH ________________________________________________________________________________
| 828 |V03AC03| DEFERASIROXUM**** | Protocol: V002D | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ V03AC03 DEFERASIROXUM COMPR. DISP. 125 mg EXJADE 125 mg 125 mg NOVARTIS EUROPHARM LTD.
EXJADE 250 mg 250 mg NOVARTIS EUROPHARM LTD. V03AC03 DEFERASIROXUM COMPR. DISP. 500 mg EXJADE 500 mg 500 mg NOVARTIS EUROPHARM LTD. ________________________________________________________________________________
| 830 |D06AA04| TETRACYCLINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ D06AA04 TETRACYCLINUM UNGUENT 3,00% TETRACICLINA CLORHIDRAT 3% ANTIBIOTICE SA ________________________________________________________________________________ ______________________________________________________________________________ | 831 |D06AX01| ACIDUM FUSIDICUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ D06AX01 ACIDUM FUSIDICUM CREMA 2,00% FUCIDIN(R) 2% LEO PHARMACEUTICAL PRODUCTS
FUCIDIN(R) 2% LEO PHARMACEUTICAL PRODUCTS
________________________________________________________________________________ ______________________________________________________________________________ | 832 |D06BA01| SULFADIAZINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ D06BA01 SULFADIAZINUM CREMA 1,00% DERMAZIN(R) 1% 1% LEK PHARMACEUTICALS D.D. ________________________________________________________________________________ ______________________________________________________________________________ | 833 |D07CA01| COMBINATII (ACIDUM FUSIDICUM + | Protocol: D001L | | | | HYDROCORTISONUM) | | |_______|_______|____________________________________________|_________________| ________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ D07CA01 COMBINATII (ACIDUM CREMA FUSIDICUM + HYDROCORTISONUM) FUCIDIN(R) H LEO PHARMACEUTICAL PRODUCTS
________________________________________________________________________________ ______________________________________________________________________________ | 834 |D07CC01| COMBINATII | Protocol: D001L | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ D07CC01 COMBINATII CREMA BELOGENT A & G MED TRADING S.R.L. DIPROGENTA(R) SCHERING PLOUGH EUROPE TRIDERM(R) SCHERING PLOUGH EUROPE
BELOGENT A & G MED TRADING S.R.L. DIPROGENTA(R) SCHERING PLOUGH EUROPE TRIDERM SCHERING PLOUGH EUROPE ________________________________________________________________________________
| 836 |J01AA07| TETRACYCLINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J01AA07 TETRACYCLINUM CAPS. 250 mg TETRACICLINA 250 mg 250 mg EUROPHARM SA TETRACICLINA SANDOZ 250 mg 250 mg SANDOZ SRL ________________________________________________________________________________
| 838 |N03AB02| PHENYTOINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ N03AB02 PHENYTOINUM COMPR. 100 mg FENITOIN 100 mg 100 mg GEDEON RICHTER ROMANIA SA
PHENHYDAN(R) SOLUTIE 50 mg/ml DESITIN INJECTABILA ________________________________________________________________________________ SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.3: HIPERTENSIUNEA PULMONARĂ ______________________________________________________________________________ | 839 |C02KX01| BOSENTANUM** | Protocol: CI01I | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ C02KX01 BOSENTANUM COMPR. FILM. 125 mg TRACLEER 125 mg 125 mg ACTELION REGISTRATION LTD.
| 840 |G04BE03| SILDENAFILUM** | Protocol: CI01I | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ G04BE03 SILDENAFILUM COMPR. FILM. 20 mg REVATIO 20 mg 20 mg PFIZER LTD. ________________________________________________________________________________ SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.4: MUCOVISCIDOZA ______________________________________________________________________________ | 841 |J01FA09| CLARITHROMYCINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J01FA09 CLARITHROMYCINUM GRAN. PT. SUSP. ORALA 125 mg/5 ml FROMILID(R) 125 mg/5 ml 125 mg/5 ml KRKA D.D. KLABAX 125 mg/5 ml 125 mg/5 ml TERAPIA S.A. KLACID(R) 125 mg/5 ml ABBOTT SPA LEKOKLAR 125 mg/5 ml 125 mg/5 ml SANDOZ S.R.L. J01FA09 CLARITHROMYCINUM COMPR. FILM. 250 mg CLAR 250 250 mg MEDICAROM GROUP S.R.L. CLARITROMICINA 250 mg 250 mg OZONE LABORATORIES LTD. FROMILID 250 250 mg KRKA D.D. NOVO MESTO KLABAX 250 mg 250 mg TERAPIA S.A. KLACID(R) 250 mg ABBOTT SPA KLERIMED(R) 250 250 mg MEDOCHEMIE LTD. LEKOKLAR(R) 250 mg 250 mg LEK PHARMACEUTICALS D.D. J01FA09 CLARITHROMYCINUM GRAN. PT. SUSP. ORALA 250 mg/5 ml KLABAX 250 mg/5 ml 250 mg/5 ml TERAPIA S.A. LEKOKLAR 250 mg/5 ml 250 mg/5 ml SANDOZ SRL
CLAR 500 500 mg MEDICAROM GROUP S.R.L. CLARITROMICINA 500 mg 500 mg OZONE LABORATORIES LTD. FROMILID 500 500 mg KRKA D.D. NOVO MESTO KLABAX 500 mg 500 mg TERAPIA S.A. KLERIMED(R) 500 500 mg MEDOCHEMIE LTD. LEKOKLAR(R) 500 mg 500 mg LEK PHARMACEUTICALS D.D.
MODIF.
KLABAX MR 500 mg 500 mg TERAPIA S.A. LEKOKLAR XL 500 mg 500 mg LEK PHARMACEUTICALS D.D. J01FA09 CLARITHROMYCINUM COMPR. FILM. ELIB. PREL 500 mg FROMILID(R) UNO 500 mg KRKA D.D. KLACID SR 500 mg ABBOTT LABORATORIES LTD.
KLACID I.V. 500 mg ABBOTT LABORATORIES LTD. ________________________________________________________________________________
| 842 |J01GB01| TOBRAMYCINUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J01GB01 TOBRAMYCINUM SOL. INHAL. 300 mg/5 ml TOBI(R) 300 mg/5 ml NOVARTIS PHARMA GMBH
| 843 |R05CB13| DORNAZA ALFA** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ R05CB13 DORNAZA ALFA SOL. INHAL. 1 mg/ml PULMOZYME 1 mg/ml ROCHE ROMANIA S.R.L. ________________________________________________________________________________ SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.5: BOLI NEUROLOGICE DEGENERATIVE/INFLAMATORII (POLIRADICULONEVRITA PRIMITIVĂ, POLINEUROPATIE INFLAMATORIE CRONICĂ DEMIELINIZANTĂ, SCLEROZA LATERALĂ AMIOTROFICĂ) ŞI MIASTENIA GRAVIS ______________________________________________________________________________ | 844 |N07XX02| RILUZOLUM** | Protocol: N024G | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ N07XX02 RILUZOLUM COMPR. FILM. 50 mg RILUTEK 50 mg 50 mg AVENTIS PHARMA SA ________________________________________________________________________________ SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.6: OSTEOGENEZA IMPERFECTA ______________________________________________________________________________ | 846 |M05BA03| ACIDUM PAMIDRONICUM | Protocol: M002Q | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ M05BA03 ACIDUM PAMIDRONICUM LIOF. + SOLV. PT. SOL. 15 mg PERF. AREDIA(R) 15 mg 15 mg NOVARTIS PHARMA GMBH M05BA03 ACIDUM PAMIDRONICUM CONC. PT. SOL. PERF. 15 mg/ml PAMIDRONAT TORREX 15 mg/ml TORREX CHIESI PHARMA GMBH M05BA03 ACIDUM PAMIDRONICUM LIOF. PT. SOL. PERF. 30 mg I.V.
PAMIRED 30 30 mg DR. REDDY'S LABORATORIES M05BA03 ACIDUM PAMIDRONICUM LIOF. PT. SOL. PERF. 60 mg I.V.
PAMIRED 60 60 mg DR. REDDY'S LABORATORIES ________________________________________________________________________________ SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.7: SINDROM PRADER WILLI ______________________________________________________________________________ | 847 |H01AC01| SOMATROPINUM** | Protocol: H011Q | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H01AC01 SOMATROPINUM SOL. INJ. 10 mg/1.5 ml NORDITROPIN 10 mg/1.5 ml NOVO NORDISK A/S SIMPLEX x 10 mg/1,5 ml H01AC01 SOMATROPINUM SOL. INJ. 10 mg/2 ml NUTROPINAq 10 mg/2 ml 10 mg/2 ml IPSEN LIMITED H01AC01 SOMATROPINUM SOL. INJ. 3,3 mg/ml OMNITROPE 3,3 mg/ml 3,3 mg/ml SANDOZ GMBH H01AC01 SOMATROPINUM LIOF. + SOLV. PT. SOL. 4 mg (12 ui) INJ.
ZOMACTON 4 mg (12 ui) FERING GMBH H01AC01 SOMATROPINUM PULB. + SOLV. PT. SOL. 5.3 mg/ml (16 ui) INJ.
GENOTROPIN(R) 16 ui (5.3 mg) 5.3 mg/ml (16 ui) PFIZER EUROPE MA EEIG H01AC01 SOMATROPINUM SOL. INJ. 5 mg/1.5 ml NORDITROPIN 5 mg/1.5 ml NOVO NORDISK A/S SIMPLEX x 5 mg/1.5 ml ________________________________________________________________________________ SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.8: BOALA FABRY ______________________________________________________________________________ | 848 |A16AB04| AGALSIDASUM BETA** | Protocol: A014E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A16AB04 AGALSIDASUM BETA PULB. PT. CONC. PT. 35 mg SOL. PERF. FABRAZYME 35 mg 35 mg GENZYME EUROPE BV ________________________________________________________________________________
| 849 |A16AB07| ALGLUCOSIDASUM ALPHA** | Protocol: A030Q | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A16AB07 ALGLUCOSIDASUM ALPHA PULB. PT. CONC. PT. 50 mg SOL. PERF. MYOZYME 50 mg 50 mg GENZYME EUROPE B.V. ________________________________________________________________________________
| 850 |A11CC02| DIHYDROTACHYSTEROLUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A11CC02 DIHYDROTACHYSTEROLUM PICATURI ORALE-SOL 0.1 mg/ml TACHYSTIN 0.1 mg/ml CHAUVIN ANKERPHARM GMBH
A.T. 10(R) 1 mg/ml MERCK KGAA ________________________________________________________________________________
| 851 |A11CC03| ALFACALCIDOLUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A11CC03 ALFACALCIDOLUM CAPS. MOI 0.25 µg ALPHA D3 0,25 µg 0.25 µg TEVA PHARMACEUTICALS SRL
ALPHA D3 0.50 µg 0.50 µg TEVA PHARMACEUTICALS S.R.L. ________________________________________________________________________________ ______________________________________________________________________________ | 852 |A11CC04| CALCITRIOLUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A11CC04 CALCITRIOLUM CAPS. MOI 0.25 µg ROCALTROL 0.25 µg ROCHE ROMANIA S.R.L. ________________________________________________________________________________ ______________________________________________________________________________ | 853 |G03CA03| ESTRADIOLUM | | |_______|_______|____________________________________________|_________________|
Yüklə 4,39 Mb. Dostları ilə paylaş:
|